HuMAB companies Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : HuMAB companies

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: nigel bates who started this subject	3/11/2003 5:10:10 PM
From: nigel bates	of 1022

(XOMA)...License fee revenue in 2002 increased to $16.8 million from $4.8 million in 2001, reflecting license fees from agreements with MorphoSys AG, Dyax Corp. and Cambridge Antibody Technology Limited signed in 2002... Message 18687359

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next